Tizanidine
Sirdalud and Sirdalud 4 mg are different trade names for the same medicine.
The active substance of Sirdalud is tizanidine hydrochloride, which reduces increased muscle tone.
Sirdalud is a centrally acting muscle relaxant. It acts mainly on the spinal cord and reduces excessive muscle tone.
Sirdalud is used for:
Follow the doctor's instructions carefully.
If any of these points apply to the patient, they should not take Sirdalud and inform their doctor.
Before starting treatment with Sirdalud, discuss it with your doctor or pharmacist, especially:
If any of these points apply to the patient, they should inform their doctor.
Sirdalud is not recommended for use in children.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.
It is especially important to inform your doctor about taking any of the following medicines:
Alcohol may enhance the sedative effect of the medicine, so it should be avoided during treatment with Sirdalud.
In pregnancy and during breastfeeding, if there is a suspicion that the woman is pregnant, or if she plans to become pregnant, she should consult her doctor before taking Sirdalud. Sirdalud may have a harmful effect on the unborn child.
Sirdalud should not be used during pregnancy.
Sirdalud should not be used during breastfeeding.
Sexually active women of childbearing potential should have a pregnancy test before starting treatment with Sirdalud and use effective contraception during treatment and for at least one day after stopping Sirdalud.
They should discuss the choice of a suitable contraceptive method with their doctor at this time.
If the patient experiences drowsiness, dizziness, or other symptoms of hypotension (such as cold sweats, "feeling empty in the head") during treatment with Sirdalud, they should not drive or operate machinery.
If the patient has been diagnosed with intolerance to some sugars (e.g., lactose), they should consult their doctor before taking the medicine.
The standard dosing regimen for Sirdalud is described below. This medicine should always be taken according to the doctor's instructions. If you have any doubts, consult your doctor or pharmacist. Do not change the prescribed dose or stop taking the medicine without consulting your doctor.
Sirdalud tablets can be taken with or without food.
Sirdalud is recommended in a dose of 2 mg to 4 mg, three times a day. In severe cases, an additional dose of 2 mg or 4 mg can be taken before bedtime to minimize the sedative effect.
The doctor will adjust the dose individually for the patient.
Initially, no more than 6 mg per day should be administered, and the daily dose should be divided into three doses.
The daily dose may be gradually increased by 2 mg to 4 mg at weekly or biweekly intervals.
The optimal response is usually achieved with a daily dose of 12 mg to 24 mg, divided into 3 or 4 equal doses. The daily dose should not exceed 36 mg.
If the patient feels that the effect of the medicine is too strong or too weak, they should consult their doctor or pharmacist.
In case of accidental overdose, the patient should immediately contact their doctor or the nearest poison control center or go to the nearest hospital emergency department.
If a dose of Sirdalud is missed, it should be taken as soon as possible. However, if there is less than 2 hours before the next dose, the missed dose should not be taken, and the next dose should be taken at the usual time.
A double dose should not be taken to make up for the missed dose.
Do not stop taking Sirdalud without consulting your doctor first. The doctor may recommend gradually reducing the dose before deciding to stop the medicine completely, which will reduce the risk of withdrawal symptoms. Withdrawal symptoms include hypertension (high blood pressure) and tachycardia (increased heart rate).
If you have any further doubts about taking this medicine, consult your doctor or pharmacist.
Like all medicines, Sirdalud can cause side effects, although not everybody gets them.
When smaller doses are taken, as recommended for relieving painful muscle spasms, side effects such as drowsiness, fatigue, dizziness, dry mouth, decreased blood pressure, nausea, gastrointestinal disorders, and increased transaminase activity are usually mild and transient.
When higher doses are taken, as recommended for treating increased muscle tone, side effects that occurred with smaller doses are more frequent and more severe. However, they rarely require discontinuation of the medicine. Additionally, the following side effects may occur: QT interval prolongation and torsades de pointes, hypotension, bradycardia, muscle weakness, insomnia, sleep disorders, hallucinations, and acute hepatitis.
If the patient experiences any of the above symptoms or any other side effects, they should inform their doctor.
Other side effects include those listed below. If any of the following side effects worsen, the patient should tell their doctor, pharmacist, or nurse.
common (may affect less than 1 in 10 people):
uncommon (may affect less than 1 in 100 people):
frequency not known (frequency cannot be estimated from the available data):
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects will help gather more information on the safety of the medicine.
Keep the medicine out of sight and reach of children.
Store in a temperature below 25°C.
Do not use Sirdalud after the expiry date stated on the packaging.
The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
1 tablet (with a cross-shaped notch) contains 4 mg of tizanidine (in the form of tizanidine hydrochloride 4.576 mg).
PVC/PE/PVDC/Al blisters in a cardboard box contain 10 or 30 tablets.
For more detailed information, consult the marketing authorization holder or parallel importer.
Sandoz s.r.o., Pikrtova 1737/1a, 140 00 Prague 4, Czech Republic
Novartis s.r.o., Na Pankráci 1724/129, 140 00 Prague 4, Czech Republic
Novartis Pharma GmbH, Roonstrasse 25 and Obere Turnstrasse 8-10, 90429 Nuremberg, Germany
Novartis Farmaceutica S.A., Gran Vía de les Corts Catalanes 764, 08013 Barcelona, Spain
InPharm Sp. z o.o.
Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
Chełmżyńska 249
04-458 Warsaw
Pharma Innovations Sp. z o.o.
Jagiellońska 76
03-301 Warsaw
Marketing authorization number in the Czech Republic, the country of export:63/209/88-B/C
Parallel import authorization number:317/20
[Information about the registered trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.